^Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.
^Lévesque D (1996). „Aminotetralin drugs and D3 receptor functions. What may partially selective D3 receptor ligands tell us about dopamine D3 receptor functions?”. Biochemical Pharmacology. 52 (4): 511—8. PMID8759022. doi:10.1016/0006-2952(96)00239-0.
^Arvidsson LE, Johansson AM, Hacksell U, Nilsson JL, Svensson K, Hjorth S, Magnusson T, Carlsson A, Andersson B, Wikström H (1987). „(+)-cis-8-Hydroxy-1-methyl-2-(di-n-propylamino)tetralin: a potent and highly stereoselective 5-hydroxytryptamine receptor agonist”. Journal of Medicinal Chemistry. 30 (11): 2105—9. PMID2959776. doi:10.1021/jm00394a029.
^Malmberg A, Nordvall G, Johansson AM, Mohell N, Hacksell U (1994). „Molecular basis for the binding of 2-aminotetralins to human dopamine D2A and D3 receptors”. Molecular Pharmacology. 46 (2): 299—312. PMID8078492.
^Eltayb A, Lindblom S, Oerther S, Ahlenius S (2001). „Additive hypothermic effects of the 5-HT1A receptor agonist 8-OH-DPAT and the dopamine D2/3 receptor agonist 7-OH-DPAT in the rat”. Acta Physiologica Scandinavica. 172 (3): 205—9. PMID11472307. doi:10.1046/j.1365-201x.2001.00858.x.